Application Nr Approved Date Route Status External Links
ANDA202389 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Escitalopram Oxalate Is A Selective Serotonin Reuptake Inhibitor (ssri) Indicated For: Acute And Maintenance Treatment Of Major Depressive Disorder (mdd) In Adults And Adolescents Aged 12 To 17 Years ( 1.1 ) Acute Treatment Of Generalized Anxiety Disorder (gad) In Adults ( 1.2 ) 1.1 Major Depressive Disorder Escitalopram Tablet, Is Indicated For The Acute And Maintenance Treatment Of Major Depressive Disorder In Adults And In Adolescents 12 To 17 Years Of Age [ See Clinical Studies ( 14.1 ) ]. A Major Depressive Episode (dsm-Iv) Implies A Prominent And Relatively Persistent (nearly Every Day For At Least 2 Weeks) Depressed Or Dysphoric Mood That Usually Interferes With Daily Functioning, And Includes At Least Five Of The Following Nine Symptoms: Depressed Mood, Loss Of Interest In Usual Activities, Significant Change In Weight And/or Appetite, Insomnia Or Hypersomnia, Psychomotor Agitation Or Retardation, Increased Fatigue, Feelings Of Guilt Or Worthlessness, Slowed Thinking Or Impaired Concentration, A Suicide Attempt Or Suicidal Ideation. 1.2 Generalized Anxiety Disorder Escitalopram Tablet, Is Indicated For The Acute Treatment Of Generalized Anxiety Disorder (gad) In Adults [ See Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (dsm-Iv) Is Characterized By Excessive Anxiety And Worry (apprehensive Expectation) That Is Persistent For At Least 6 Months And Which The Person Finds Difficult To Control. It Must Be Associated With At Least 3 Of The Following Symptoms: Restlessness Or Feeling Keyed Up Or On Edge, Being Easily Fatigued, Difficulty Concentrating Or Mind Going Blank, Irritability, Muscle Tension, And Sleep Disturbance.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Escitalopram Oxalate ESCITALOPRAM OXALATE ZINC6021239

Comments